Clotilde Guidetti | Neuropharmacology | Best Researcher Award

Dr. Clotilde Guidetti | Neuropharmacology | Best Researcher Award

Dr. Clotilde Guidetti, Harvard Medical School, Massachusetts General Hospital, United States.

Clotilde Guidetti is an accomplished early-career physician-scientist specializing in Child and Adolescent Neuropsychiatry. With a classical foundation and medical training from the University of Genoa, she excelled academically, earning multiple merit awards and graduating Summa Cum Laude. She completed her specialized residency at the Catholic University of Rome, further refining her clinical expertise. Clotilde’s research focus lies in neurodevelopmental disorders, behavioral interventions, and psychopharmacology in pediatric populations. She has already demonstrated promise as an independent researcher through competitive grant submissions and award-winning conference presentations. Based in Boston, she is actively shaping a career that bridges clinical care and scientific innovation.

Profile

Scopus

 

🎓 Early Academic Pursuits

Clotilde Guidetti began her academic journey with a deep-rooted passion for understanding the human mind and behavior. She earned her High School Diploma in Classical Studies from the prestigious State High School Andrea D’Oria, an early indication of her strong intellectual curiosity and dedication to learning. This foundation in classical education provided her with a broad humanistic perspective that continues to inform her clinical and research approach. She then pursued her Medical Degree at the University of Genoa, where she graduated Summa Cum Laude in 2020. Her academic record was consistently marked by distinction, earning multiple Academic Merit Awards for clinical excellence during her medical studies.

🧠 Professional Endeavors

Following her graduation, Dr. Guidetti further specialized in the field of Child and Adolescent Neuropsychiatry through a rigorous residency program at the Catholic University of Rome. Completed in November 2024, her residency was also distinguished with Summa Cum Laude honors, reflecting both her clinical acumen and compassionate engagement with young patients. Her professional training combined intensive clinical work with scholarly research, preparing her to address complex neurodevelopmental and psychiatric disorders in children and adolescents.

🔬 Contributions and Research Focus

Dr. Guidetti’s primary research interests lie at the intersection of neurodevelopment, behavioral disorders, and psychopharmacology in pediatric populations. Her clinical insights are deeply enriched by her scientific inquiries, particularly those focused on the early diagnosis and personalized treatment of neuropsychiatric conditions. She has already begun shaping her independent research path, as seen in her recent submission for the Brain & Behavior Research Foundation Young Investigator Grant in January 2025. Her project, currently under review, reflects her growing reputation as an emerging scholar in the domain of pediatric neuropsychiatry.

🏅 Accolades and Recognition

Throughout her academic and clinical journey, Clotilde Guidetti has been the recipient of multiple honors that highlight her outstanding abilities. These include three Academic Merit Awards from the University of Genoa and a prestigious Erasmus Socrates Fellowship in 2017–2018, which broadened her training in an international context. In 2022, she received the Attilio Sabato Award from the Società Italiana di Neuropsicofarmacologia (SINPF) for the best poster presentation—an achievement that not only celebrated her communication skills but also her innovative scientific thinking in neuropsychopharmacology.

🌍 Impact and Influence

Though early in her career, Dr. Guidetti has already begun to leave a meaningful mark on the field of child and adolescent mental health. Her dual focus on clinical excellence and academic inquiry ensures that her work resonates both within medical communities and in the lives of the families she serves. With a practice grounded in empathy and scientific rigor, she exemplifies the new generation of clinician-scientists committed to transforming mental health care for the most vulnerable populations.

🧬 Legacy and Future Contributions

As she looks to the future, Clotilde Guidetti aims to expand her contributions to academic psychiatry through collaborative research, cross-disciplinary studies, and the mentorship of emerging professionals in the field. Her continued involvement in national and international research networks promises to amplify her influence, paving the way for innovative treatments and holistic models of care in pediatric neuropsychiatry. Her vision is firmly centered on early intervention, neurodevelopmental resilience, and the integration of clinical practice with cutting-edge neuroscience.

📚 Academic Footprint

Dr. Guidetti currently resides and practices in Boston, Massachusetts, where she continues to build her clinical and research profile. Her dual base—rooted in Italy and expanding into the United States—places her at the nexus of transatlantic collaboration. With each project and presentation, she further refines her expertise and extends her academic footprint, fostering a dynamic career defined by global engagement, intellectual integrity, and unwavering commitment to child and adolescent mental health.

Publication

  • Title: Antidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis

  • Authors: Guidetti, Clotilde; Feeney, Anna; Hock, Rebecca S.; Fava, Maurizio; Papakostas, George I.

  • Year: 2024

 

📝 Conclusion

Dr. Guidetti embodies the ideal of a compassionate clinician and rigorous academic, poised to make significant contributions to the future of child and adolescent mental health. Her career so far reflects a seamless blend of scholarly excellence, clinical sensitivity, and a drive to push the boundaries of understanding in neuropsychiatry. As she continues to expand her research and collaborative efforts globally, her work promises to influence both scientific discourse and practical approaches in mental health care—building a legacy rooted in evidence, empathy, and innovation.

 

Baoying Huang | Pathogen Biology | Best Researcher Award

Baoying Huang | Pathogen Biology | Best Researcher Award

Ms. Baoying Huang,  National Institute for Viral Disease Control and Prevention, China.

Dr. Baoying Huang, a distinguished professor at the Biotech Center for Viral Disease Emergency, China CDC, has over two decades of experience in combating viral diseases. Her expertise lies in vaccine and antiviral drug development for emerging and re-emerging infectious diseases, including COVID-19, monkeypox, and other human coronaviruses.

 

profile

Scopus

🎓 Education Experience

2008.09–2011.07: Doctor of Medicine, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC.2005.09–2008.07: Master of Biology, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC. 2001.09–2005.07: Bachelor of Biology,
Life Science Department, Nan Hua University, China.

👩‍🔬 Professional Experience

2020.07–Present:  Professor, China CD ,Focus: Vaccine and antiviral drug R&D for SARS-CoV-2 and poxvirus diseases, including COVID-19 and monkeypox. Key Role: Participated in COVID-19 Emergency Projects for SARS-CoV-2 variant monitoring in China.2015.07–2020.07:  Associate Professor, China CDC. Focus: Vaccine and antiviral drug R&D for emerging infectious diseases like influenza and coronaviruses (SARS-CoV, MERS-CoV).2015.04–2015.06:  Assistant Professor, China CDC. Global Health Support Program: Worked in Sierra Leone to establish Ebola lab systems, improving public health infrastructure.2011.07–2015.07: Assistant Professor, China CDC. Focus: Pathogenic molecular mechanisms of influenza viruses, pseudo-virus applications, and gene-engineered vaccines. 2005.09–2011.07:  Graduate Researcher, IVDC, China CDC. Specialization: Developing universal influenza vaccines for cross-protection against various strains.

🔬 Research Focus

Baoying Huang’s work is dedicated to:Vaccine Development: COVID-19 vaccines (BBIBP-CorV, mRNA vaccines) and pan-orthopoxvirus solutions.Emerging Diseases: Countermeasures for SARS-CoV-2, monkeypox, and other viral threats.Diagnostics: Whole-genome sequencing and real-time PCR for virus detection and monitoring.Therapeutics: Screening novel antivirals targeting viruses like SARS-CoV-2 and monkeypox.Key achievements include:Leading the development of Sinopharm COVID-19 vaccine, later approved by WHO for Emergency Use Listing.Establishing monitoring systems for SARS-CoV-2 variants and assessing their impact on public health measures. Advancing monkeypox vaccine research and identifying promising antiviral compounds against orthopoxviruses.

📚 Publications

  • Title: Molecular architecture of monkeypox mature virus
    • Authors: Hong, Y., Huang, B., Zhang, J., Tan, W., Li, S.
    • Year: 2024

 

  • Title: Vaccinia virus Tiantan strain blocks host antiviral innate immunity and programmed cell death by disrupting gene expression
    • Authors: Wu, C., Zhang, Z., Li, Z., Deng, Y., Tan, W.
    • Year: 2024

 

  • Title: A clinically used anti-human papilloma virus agent (3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin) has a potential for topical application to prevent sexual transmission of monkeypox virus
    • Authors: Sha, Y., Huang, B., Hua, C., Tan, W., Jiang, S.
    • Year: 2024

 

  • Title: Development of a multiplex real-time PCR assay for the simultaneous detection of mpox virus and orthopoxvirus infections
    • Authors: Fan, Z., Xie, Y., Huang, B., Tan, W., Guo, F.
    • Year: 2024

 

  • Title: Accurate determination of the whole genome sequencing and open reading frames composition of non-replicating Tiantan strain of vaccinia virus based on novel long read sequencing platform
    • Authors: Zhang, Z., Wu, C., Li, H., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Characterization of whole genomes from recently emerging Mpox cases in several regions of China, 2023
    • Authors: Wu, C., Cui, L., Pan, Y., Wang, Q., Tan, W.
    • Year: 2024

 

  • Title: Intranasal immunization with single-dose vaccine based on recombinant influenza virus H1N1 expressing the extracellular domain of respiratory syncytial virus G protein induces robust immunity and protection in mice
    • Authors: Han, R., Wang, D., Wang, T., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Rapid identification of full-length genome and tracing variations of monkeypox virus in clinical specimens based on mNGS and amplicon sequencing
    • Authors: Wu, C., A, R., Ye, S., Lu, J., Tan, W.
    • Year: 2024

 

  • Title: Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population
    • Authors: Li, M., Guo, Y., Deng, Y., Gao, G.F., Liu, J.
    • Year: 2024

 

  • Title: Identification of the VP37 pocket of monkeypox virus as a promising target for pan-orthopoxvirus inhibitors through virtual screening and antiviral assays
    • Authors: Huo, S., Wu, L., Huang, B., Xu, Z., Tan, W.
    • Year: 2024

 

Conclusion

Dr. Huang’s career exemplifies unwavering dedication to improving public health through innovation in vaccine development, antiviral research, and diagnostic technologies. Her contributions to tackling global health challenges, such as the COVID-19 pandemic and monkeypox outbreaks, have significantly impacted infectious disease prevention and control worldwide. As viruses continue to evolve, her pioneering work remains a cornerstone in safeguarding global health.